Table 2 Comparison between baseline, 6 month and 12 month time-point measurements after anti-VEGF treatment

FAZ area mm²

(SD)

0.307

(± 0.133)

0.3

(± 0.1)

0.313

(± 0.1)

0.6^†

0.5*

0.10*

Perimeter mm²

(SD)

2.415

(± 0.692)

2.4

(± 0.5)

2.394

(± 0.4)

0.7^†

0.9*

0.3*

Choroid thickness µm

(SD)

335.9

(± 39.1)

347.2

(3 ± 8.1)

336.8

(± 44.6)

0.7^†

0.4*

0.3^∆

Choriocapillaris whole image density %

(SD)

62.6

(± 6.1)

63.4

(± 6.4)

63.9

(± 6.9)

0.9^†

0.7*

0.5*

Choriocapillaris foveal area density %

(SD)

61.2

(± 7.4)

60.6

(± 8.8)

59.1

(± 7.9)

0.85^†

0.8^∆

0.3*

Choriocapillaris parafoveal area density %

(SD)

61.9

(± 6.6)

63.2

(± 6.6)

64.1

(± 7.3)

0.9^†

0.5*

0.7*

Retinal whole image density %

(SD)

46.9

(± 5.1)

45.3

(± 5.2)

45.7

(± 5.0)

0.5^†

0.4*

0.5*

Retinal foveal area density %

(SD)

27.6

(± 5.9)

25.2

(± 6.9)

25.0

(± 6.8)

0.2^†

0.3*

0.07*

Retinal parafoveal area density %

(SD)

49.0

(± 5.6)

47.5

(± 5.7)

48

(± 4.9)

0.6^†

0.1^∆

0.6*

CST µm

(SD)

397.1

(± 93.2)

300.4

(± 67.8)

294.2

(± 71.5)

0.005 ^†

0.001*

0.7*

Visual acuity ETDRS

(SD)

69.6

(± 7.9)

72.2

(± 7.9)

73.9

(± 7.2)

0.3^†

0.2*

0.3*